{"product_id":"ingibitory-kinaz-von-punam-kaswan","title":"Ingibitory kinaz","description":"\u003cp\u003eOdnoj iz naibolee znachimyh mishenej dlq lekarstw w XXI weke qwlqetsq semejstwo proteinkinaznyh fermentow. Suschestwuet 62 terapewticheskih sredstwa, razreshennyh FDA, kotorye naprawleny na okolo dwuh desqtkow razlichnyh belkow. Za isklücheniem Netarsudila, primenqemogo dlq lecheniq opticheskih glaz, i temsirolimusa dlq lecheniq karcinomy pochechnyh kletok, wse razreshennye FDA preparaty bezopasny dlq peroral'nogo primeneniq. Klüchewymi obschimi mishenqmi preparatow qwlqütsq BCR-Abl, B-Raf, sosudistye receptory, VEGFR i EGFR, a takzhe ALK. K chislu 8 odobrennyh preparatow iz 2020 goda otnosqtsq: tukatinib, ripretinib, selumetinib, kapmatinib, pemigatinib pralsetinib, selperkatinib i awapritinib. Adenin-swqzywaüschij karman zanqt podawlqüschim bol'shinstwom licenzirowannyh ingibitorow kinaz. Ih klassifikaciq osnowana na sposobnosti katalizirowat' prewraschenie terminal'nogo fosfata ATF w substraty, soderzhaschie ostatki serina, treonina ili tirozina. V swqzi s disregulqciej aktiwnosti proteinkinaz pri mnogih zabolewaniqh, wklüchaq rak, äto semejstwo fermentow stalo odnoj iz wazhnejshih lekarstwennyh mishenej w XXI weke. Suschestwuet 72 terapewticheskih preparata, odobrennyh FDA, kotorye naprawleny na okolo dwuh desqtkow razlichnyh proteinkinaz.\u003c\/p\u003e\u003cdiv class=\"aw-variant-hidden-subtitle-div\" id=\"aw-variant-subtitle-9786206871637\"\u003e\u003ch3\u003eObzor\u003c\/h3\u003e\u003c\/div\u003e","brand":"Autorenwelt Shop","offers":[{"title":"Softcover - 9786206871637","offer_id":47349753774405,"sku":"9786206871637","price":43.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0940\/0622\/files\/ccd4b4ae-984c-4fcc-a891-6cbc0d7e9269.jpg?v=1750140995","url":"https:\/\/shop.autorenwelt.de\/en\/products\/ingibitory-kinaz-von-punam-kaswan","provider":"Autorenwelt Shop","version":"1.0","type":"link"}